Biotech Mailbag: Recap on GenVec By Adam Feuerstein About this article: Welcome back to the Biotech Mailbag. My column on GenVec and the interim data from the phase III study of the company's pancreatic cancer drug TNFerade brought in a slew of email, mostly positive, I'm happy to report. John B. writes, "Thanks for the thorough coverage of GenVec. I didn't wait for your, or anyone else's interpretation, though. I was up early in anticipation of GenVec's results today, and I didn't like what I saw overall. I'm worried about cash for the future as well. I liquidated my position at 6:30 a.m. California time. It's been four years, and here we are back to 60 cents. "There's time to buy again before the 2009 study results. In the meantime, I'm back to trading GenVec. The 60 cents level will provide a nice swing trade for me and many others, and another reason the stock price will not see... Or, call us at 1-866-321-TSCM (8726) Monday-Friday, 8 a.m.-6 p.m. ET. Outside the U.S. and in Canada, call 1-212-321-5200. More Stories From RealMoney Durable Goods Up Move Down the Tech Food Chain Jobless Claims Still High Bulls' Tenacity Is the Big Question Mark Should You Buy It? Pharmaceutical Product Development Bad News Trumps All Support for Banks Holds, For Now Bummer, Yields Are on the Rise Money on the Line Makes a Big Difference Structured Products: Unsafe at Any Price MORE STORIES FROM REALMONEY

If you choose a 14-day free trial of RealMoney and you do NOT call to cancel within those 14 days, you will pay $129.95 — a $100 savings off the regular annual subscription price of $229.95. Unless you cancel before the end of that year, your subscription will automatically renew for another year at the then-current subscription price.

Offer applies only to new annual subscriptions, and is subject to change at any time. Void where prohibited.

If you choose a monthly subscription, you pay $34.95 per month. You will be notified if the current monthly rate of $34.95 changes at any time in the future.

TheStreet.com is a publisher. None of the contributors or their affiliates will provide you with personally tailored advice concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. From time to time, any or all of the contributors or their affiliates may hold positions in securities mentioned and they may trade for their own accounts. In cases where the position is held at the time of publication, appropriate disclosure is made.

© TheStreet.com, Inc., 14 Wall Street, 15th Floor, New York, NY 10005.